FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients

Table 3 Relationship between rs9939609 polymorphism and virologic responses to HCV treatment in HIV/HCV-coinfected patients according to HCV genotypes

HCV genotype	All patients	TT	AT	AA	P-value^(a)	aOR (95%CI)	P-value^(b)
All patients	55.1% (98/178)	64.3% (45/70)	51.8% (43/83)	40.0% (10/25)	0.026	0.58 (0.34; 0.99)	0.044
GT2/3 patients	85.5% (47/55)	92.0% (23/25)	83.3% (20/24)	66.7% (4/6)	0.125	0.43 (0.14; 1.31)	0.138
GT1/4 patients	40.7% (48/118)	48.8% (20/41)	37.9% (22/58)	31.5% (6/19)	0.171	0.59 (0.31; 1.12)	0.105

^a P-values were calculated by linear-by-linear association Chi-squared test; ^b P-values were calculated by multivariate generalized linear models (GLM) adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section). Statistically significant differences are shown in bold. 95%CI, 95% confidence interval; aOR, adjusted odds ratio; GT1/4, HCV genotype 1/4; GT2/3, HCV genotype 2/3; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SVR, sustained virologic response.

ISSN: 1741-7015